• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·CORALAB.BO
Share

Coral Laboratories Limited Stocks

₹ 524.8Last Updated 19.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 20.09M

₹ 524.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Coral Laboratories Ltd. specializes in the production of various pharmaceutical drug formulations. The company's operations are segmented geographically across Ethiopia, India, and other international territories. Its comprehensive product line encompasses solid dosage forms like tablets and capsules, liquid medications, topical treatments, ophthalmic and otic solutions, and injectable preparations. Founded on June 19, 1981, the firm's main corporate office is located in Mumbai, India.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 20:36

Why Cathie Wood's team expects Tesla's stock to rise by more than 1,000%

20.10.2026 20:11

"A Vicious Cycle": What Risks Does Rising Bond Yields Pose to the Stock Market?

20.10.2026 19:39

"The Weak Link": The risk premium on French government bonds has approached a 15-year high

20.10.2026 19:05

The success of the hair loss pill trials has boosted the developer's stock price. Should you buy them?

20.10.2026 18:41

Digital Twins: Why Kazakhstan Is Implementing Artificial Intelligence in Industry

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026